Marburg Virus Outbreak: Rwanda Reports 20 Cases

Updated Sep 30, 2024 | 09:08 AM IST

SummaryThe latest outbreak in Africa is in Rwanda, it is the Marburg virus which have so far killed 6 people. Read on to know more about it.
Marburg Virus

Credits: Canva

After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

End of Article

Changes In Speech, Pauses & Word Choice May Help Detect Alzheimer's Early; Bill Gates Calls Research 'Fascinating'

Updated Nov 22, 2026 | 03:00 PM IST

SummaryIn a research led by Dr. Marziye Eshghi from Mass General Brigham University of Health Professions in Boston, analysis of speech changes identified patients at risk of Alzheimer's accurately up to 77% of the time.
Changes In Speech, Pauses & Word Choice May Help Detect Alzheimer's Early; Bill Gates Calls Research 'Fascinating'

Credit: AI image

Speech is “really a window into brain health”, said Dr. Marilu Gorno Tempini, director of the language neurobiology laboratory at the University of California, San Francisco. The neuroscientist used the phrase while talking about developments in research related to changes in speed and dementia risk.

Described as one of the most “fascinating fields of research” by billionaire tech entrepreneur Bill Gates, speech patterns, including pauses while speaking, speaking speed, choice of words, vocabulary and sentence structure, are being studied to identify early changes in brain health.

Speech is a complex brain activity, which entails processing language, vocabulary, retrieving memories, focusing and paying attention. Changes in any of these activities could indicate a person’s cognitive decline and their risk of developing neurodegenerative disorders like Alzheimer’s.

Technological advances in artificial intelligence have made it possible to analyse speech patterns that could be recorded in everyday communications.

Also read: Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

Changes In Speech Patterns And Alzheimer’s Risk

Due to developments in the field, it has become feasible for researchers to analyse speech-related changes that reflect cognitive health.

People can record themselves, producing useful data that can be combined with brain imaging and blood tests, could be used to predict dementia risk and monitor progression of cognitive impairment.

Marziye Eshghi from Mass General Brigham University of Health Professions in Boston is leading the research in the area. She said, “We are seeing differences that humans can’t see or can’t really detect by their ears, but it’s there years and years before cognitive decline.”

Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Dr. Eshghi’s project is based on 130 different speech-related features in participants. The data is then processed through artificial intelligence algorithms and compared to established biological risk factors for Alzheimer’s disease.

After the preliminary results came out, it was observed that speech-related data was better than cognitive testing at identifying Alzheimer’s risk in cognitively unimpaired older people.

“What we are doing is capturing individuals who are at higher risk of developing Alzheimer’s disease, but they are still not showing any symptoms,” said Dr. Eshghi.

Speech analysis could also help researchers determine those at greater risk among people who have tested positive for Alzheimer’s biomarkers, Melissa Lee, who directs digital and A.I. at the nonprofit Alzheimer’s Drug Discovery Foundation, told New York Times.

She said, “If we have two people with positive blood tests, one shows decline and one won’t, and we’d use their speech to tell them apart.”

Also read: Can Unhappy Marriages Increase Dementia Risk? Study Finds 38% Chance

Speech Analysis Identified Patients At Risk Of Alzheimer’s Up To 77% Of The Time

In one of the studies, 49 people without cognitive impairment were classified as low-risk, moderate-risk or high-risk based on levels of an Alzheimer’s-related protein in their blood and whether they had a genetic variant commonly observed with increased risk.

Researchers then analyzed speech recordings, without knowing participants’ risk categories, and tested whether a computer model could determine which participants were in which group.

In preliminary results, the speech-based analysis classified participants accurately up to 77 percent of the time. This fared much better than the 47 percent accuracy of common cognitive testing models.

Changes in speech pattern may also be used in analysing other health conditions like depression, Parkinson’s disease, and diabetes. These three conditions are often accompanied with subtle changes in voice like talking speed, slurred speech, and vocal hoarseness.

End of Article

India Administers 1 Crore HPV Vaccine Doses In 9 Months, Covering 87% Of Eligible Girls

Updated Nov 22, 2026 | 11:00 AM IST

SummaryThe Ministry of Health and Family Welfare recently announced that India has administered HPV vaccine in nearly 87% of eligible teenage girls, which equals roughly 1.2 crore girls.
India Administers 1 Crore HPV Vaccine Doses In 9 Months, Covering 87% Of Eligible Girls

Credit: AI image

India has administered more than 1 crore doses of the human papillomavirus (HPV) vaccine in less than nine months since it launched its nationwide vaccination campaign.

This means the country has covered nearly 87% of its annual target cohort of 14-year-old girls. The milestone marks a major step towards preventing cervical cancer, which is largely caused by repeated HPV infections.

India Hits Its HPV Vaccination Target

Also read: World Cervical Cancer Elimination Day 2026: WHO Calls For HPV Vaccination, Screening & Early Treatment

According to the Ministry of Health and Family Welfare, the campaign has reached nearly 87% of its estimated annual target of 1.2 crore girls, based on 2021 population estimates from the Registrar General of India.

The vaccination drive was started in February 2026 and provides free, voluntary single-dose HPV vaccination to eligible 14-year-old girls at designated government health facilities.

Six states, Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar, have reported 100% coverage of their target populations.

Among other states, Assam has recorded 95.63% coverage, followed by Telangana at 95.28%, Karnataka at 93.16% and Uttarakhand at 90.17%. Chhattisgarh and Rajasthan have crossed 80% coverage, while Kerala, Tamil Nadu and Odisha have achieved more than 70%.

In terms of the number of girls vaccinated, Uttar Pradesh leads with more than 29.33 lakh, followed by Bihar with 13.70 lakh and Gujarat with 7.75 lakh.

How Does HPV Vaccine Prevent Cervical Cancer?

Also read: Menstrual Blood-Based Self-Sampling Cervical Cancer Test Gets Patent-Know Everything About It

Almost all cervical cancer cases are caused by repeated infection with high-risk types of human papillomavirus, a common virus transmitted through sexual contact.

Most HPV infections clear naturally without causing health problems. The progression from HPV infection to cervical cancer generally takes 15–20 years, but it can happen faster in women with weakened immune systems.

HPV vaccination helps prevent infections caused by HPV types that cause cancer before exposure to the virus. Vaccinating girls at age 14 aims to provide protection before they are likely to encounter HPV. The vaccine is a preventive intervention. It does not treat an existing HPV infection or cervical cancer.

India Is Expanding HPV Vaccination Coverage

Also read: About 7.9% Of Women In Kerala Are Affected By Cervical Cancer; Why Early Detection Is Important

The government says the campaign's progress has been supported by coordination between the Centre, state governments, district administrations, healthcare professionals and frontline workers, including ASHAs and ANMs.

The U-WIN digital platform is being used for beneficiary tracking, monitoring vaccination coverage, maintaining digital records and identifying eligible girls yet to receive the vaccine. Parents can also use the platform to book vaccination slots and obtain digital certificates.

Vaccination sessions are conducted at designated government health facilities under the supervision of trained medical officers. Arrangements have also been made for identifying and managing adverse events after vaccination.

Cervical Cancer Prevention

Cervical cancer remains a major public health concern in India, despite being largely preventable through HPV vaccination.

The World Health Organization's cervical cancer elimination strategy aims for 90% of girls to be fully vaccinated against HPV by age 15, 70% of women to undergo screening by ages 35 and 45, and 90% of women diagnosed with cervical disease to receive appropriate treatment.

Cervical cancer prevention entails HPV vaccination, regular screening and timely treatment of precancerous changes.

End of Article

Pancreatic Cancer Breakthrough? New Drug Combo Controls Tumour Growth In 90% Of Patients

Updated Nov 22, 2026 | 09:37 AM IST

SummaryThe combination includes daraxonrasib, an experimental targeted cancer drug, and two chemotherapy medicines, gemcitabine and nab-paclitaxel, designed to treat one of the most deadliest cancers.
Pancreatic Cancer Breakthrough? New Drug Combo Controls Tumour Growth In 90% Of Patients

Credit: AI image

In what can be described as a major breakthrough, a new treatment combination has shown tremendous promise in advanced pancreatic cancer treatment. A recent early-stage clinical trial showed that the combo shrank tumours in more than 60% of patients and controlled disease progression in 90% of patients.

The findings raise hope for pancreatic cancer, which is often diagnosed late as well as has limited treatment options. Despite positive outcomes, larger trials are needed to establish how much the treatment improves survival.

More About The Pancreatic Cancer Treatment Trial

Also read: Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

The combination includes daraxonrasib, an experimental targeted cancer drug, alongside two chemotherapy medicines, gemcitabine and nab-paclitaxel.

The updated results from the Phase 1/2 RMC-GI-102 trial were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The study involved 61 patients with metastatic pancreatic adenocarcinoma who had not previously received treatment for their metastatic disease. Participants received the combination and were followed for a median of 18.3 months.

A 90.2% control in disease was reported, meaning the cancer either shrank or remained stable. The objective response rate, which measures tumours that shrank significantly or disappeared, was 60.7%. This included complete responses in 8.2% of patients, whose tumours were no longer detected.

Median progression-free survival was 12.8 months, meaning patients lived a median of nearly 13 months without their cancer progressing or dying. The estimated proportion of patients alive at one year was 76.6%.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings, said “this is the closest to cure”. He also said that he had never seen so many tumours disappear in patients whose cancer had spread.

He also said, “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival."

He added, “The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”

How Does The New Drug Combination Work?

Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Daraxonrasib, also known as RASONQUE, targets RAS, which drives cell growth. Mutations in RAS, especially KRAS, can keep these growth signals on, allowing pancreatic cancer cells to multiply uncontrollably.

The drug is designed to inhibit active RAS proteins and disrupt the signals that cancer cells depend on for growth and survival. Researchers are combining it with chemotherapy to attack the cancer through different mechanisms.

Gemcitabine interferes with cancer cell DNA synthesis, while nab-paclitaxel disrupts microtubules, structures essential for cell division. Combining these drugs with targeted RAS inhibition could produce more sustained responses.

A Major Breakthrough

Also read: Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Pancreatic cancer remains one of the most difficult cancers to treat once it has spread beyond the pancreas. Many patients are diagnosed at an advanced stage, when surgery may no longer be possible.

The RAS signalling mechanism has long been considered a challenging target for cancer treatment. The development of drugs capable of fighting this has therefore opened a new avenue of research, especially pancreatic cancers driven by RAS mutations.

The trial's response rates and duration of disease control are encouraging. However, it was a small, open-label study without a chemotherapy comparison group.

Researchers cannot determine yet how much of the benefit came from daraxonrasib rather than chemotherapy or whether the combination will significantly extend survival.

Daraxonrasib is being investigated in larger clinical trials to determine its effectiveness and safety. A Phase 3 trial, RASolute 303, is comparing daraxonrasib alone, daraxonrasib combined with gemcitabine and nab-paclitaxel, and chemotherapy alone in patients with previously untreated metastatic pancreatic cancer.

These results will help establish whether the promising early findings translate into a meaningful improvement in survival and whether the combination could become a new treatment option.

End of Article